Avalo Therapeutics (AVTX) vs Design Therapeutics (DSGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Design Therapeutics (DSGN) has outperformed Avalo Therapeutics (AVTX) over the past year, gaining 80.1% versus a gain of 0.7%. Over five years, DSGN leads with a -18.0% price change compared with -99.8% for AVTX. Design Therapeutics is the larger company by market cap ($701.5 million vs $689.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | DSGN |
|---|---|---|
| Share price | $12.85 | $11.21 |
| Market cap | $689.15M | $701.54M |
| 1-day change | -5.38% | -4.11% |
| YTD return | -25.22% | +24.63% |
| 1-year return | +0.74% | +80.12% |
| 5-year return | -99.79% | -17.96% |
| EPS (TTM) | $-4.31 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.27 | $17.25 |
| 52-week low | $12.51 | $5.28 |
| Distance from 52-week high | -47.05% | -35.01% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +243.04% | +93.67% |
| Average volume | 926.15K | 603.58K |
| Shares outstanding | 53.63M | 62.58M |
| Employees | 33 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DSGN has outperformed AVTX by 79.4 percentage points over the past year.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Design Therapeutics
DSGN stock →Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
AVTX vs DSGN FAQ
Which is bigger, Avalo Therapeutics or Design Therapeutics?
Design Therapeutics (DSGN) is larger, with a market capitalization of $701.54M compared with $689.15M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or DSGN?
DSGN returned +80.12% over the past 12 months, compared with +0.74% for AVTX (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Design Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.